Genor Biopharma Holdings Limited (6998.HK)

1,140 0,000 (0,00%) Alla chiusura: 04:08PM HKT

Genor Biopharma Holdings Limited

Building 6
Room 401-17 690 Bibo Road Pudong New District
Shanghai 201203
China
4007886695
https://www.genorbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 104

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Feng Guo Ph.D.	CEO & Chairman	8,24M	N/D	1970
Mr. Chengyi Weng	Vice President of Finance	N/D	N/D	N/D
Mr. Qibin Liang	Chief Technology Officer	N/D	N/D	1957
Dr. Shuhua Han Ph.D.	Chief Scientist	N/D	N/D	1959
Ms. Xiaojing Zhu	Vice President of Compliance & Administration	N/D	N/D	N/D
Mr. Tong Li M.D.	Chief Medical Officer	N/D	N/D	1969
Mr. Tak Wai Ip	Company Secretary	N/D	N/D	N/D
Mr. Jun Lin	Vice President of Quality Analysis	N/D	N/D	1985
Mr. Qingtang Duan	General Manager of Yuxi Genor	N/D	N/D	1982

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulizing crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226, which is under Phase 1/2 clinical trial to treat solid tumors. It also develops GB226, which is in Phase III clinical trial to treat 2L+ cervical cancer; in phase II trial to treat ASPS and r/r PMBCL; and in Phase I trial to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC. In addition, the company develops GB261, which is in Phase I/II clinical trial to treat NHL; and GB263T that is in Phase I/II clinical trial to treat NSCLC. Further, it develops GB221, which is in Phase III clinical trial for the treatment of HER2 + 1L/2L+ mBC; GB223 that is in Phase I clinical trial to treat GCTB and PMO; GB241, which is in Phase III clinical trial to treat 1L DLBCL; and GB251 that is in Phase I clinical trial to treat HER2 + 1L/2L+ mBC. Additionally, the company's product candidates under pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Governance aziendale

L'ISS Governance QualityScore di Genor Biopharma Holdings Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.